| Literature DB >> 30705574 |
Srwsht Saeed Abdulrahman1, Dena Nadhim Mohammad2, Marwa Abdul-Salam Hamied2, Mardin Othman Abdulqadir3.
Abstract
BACKGROUND: Salivary gland tumors are a heterogeneous group of lesions with diverse histological features. Hence they are considered as a diagnostic challenge for the pathologist. Myoepithelial cells are considered as a key in the morphogenetic process, with diverse differentiation in various salivary gland tumors. Calponin is an actin filament- associated protein that represents a sensitive marker of myoepithelial cells. Telomerase is a ribonucleoprotein that adds telomere repeats at the end of chromosomes in order to prevent replicative senescence. It has a key role in cellular immortality and tumorgenesis of various tumors. This study evaluates the immunohistochemical expression of calponin and telomerase in various salivary gland tumors.Entities:
Keywords: Calponin; Diffuse pattern; Salivary gland tumors; Telomerase
Year: 2018 PMID: 30705574 PMCID: PMC6349947 DOI: 10.1016/j.sdentj.2018.11.007
Source DB: PubMed Journal: Saudi Dent J ISSN: 1013-9052
Fig. 1Cytoplasmic expression in positive controls. A – Calponin expression in human gastric carcinoma. B – Telomerase expression in normal human tonsil tissue.
Fig. 2Calponin immune expression in normal salivary glands X400. A – Periphery of acini (arrow). B – Periphery of the intercalated duct (arrow).
Calponin immune positivity in benign salivary gland tumors in relation to pattern and intensity.
| Benign salivary gland tumors | No. of positive cases (%) | Pattern | P value | Intensity | P value | ||
|---|---|---|---|---|---|---|---|
| Focal | Diffuse | Strong | Weak | ||||
| No. (%) | No. (%) | No. (%) | No. (%) | ||||
| Pleomorphic adenoma (15) | 14 (93.3) | 2 (14.3) | 12 (85.7) | 0.02 | 9 (64.3) | 5 (35.7) | 0.1 |
| Basal cell adenoma (1) | 1 (100) | 0 | 1 (100) | 0 | 1 (100) | ||
| Warthin’s tumor (2) | 0 | 0 | 0 | 0 | 0 | ||
| Total (18) | 15 (83.3) | 2 (13.3) | 13 (86.7) | 9 (60) | 6 (40) | ||
P < 0.05 significant difference.
Calponin immune positivity in benign salivary gland tumors in relation to distributions.
| Benign salivary gland tumors | No. of positive cases (%) | Distribution | P value | |||
|---|---|---|---|---|---|---|
| Luminal positivity | Abluminal positivity | Luminal & abluminal positivity | Solid tumor (no duct) | |||
| No. (%) | No. (%) | No. (%) | No. (%) | |||
| Pleomorphic Adenoma (15) | 14 (93.3) | 1 (7.1) | 1 (7.1) | 8 (57.1) | 4 (28.6) | 0.1 |
| Basal cell adenoma (1) | 1 (1 0 0) | 0 | 0 | 1 (1 0 0) | 0 | |
| Warthin’s tumor (2) | 0 | 0 | 0 | 0 | 0 | |
| Total (18) | 15 (83.3) | 1 (6.7) | 1 (6.7) | 9 (60) | 4 (26.7) | |
Fig. 3Calponin expression in benign salivary gland tumors X400. A – Diffuse expression in pleomorphic adenoma. B – Mixed distribution in pleomorphic adenoma. C – Solid distribution in pleomorphic adenoma. D- Diffuse weak mixed distribution in basal cell adenoma.
Calponin expression in malignant salivary gland tumors in relation to pattern and intensity.
| Malignant salivary gland tumors (12) | No. of positive cases (%) | Pattern | P value | intensity | P value | ||
|---|---|---|---|---|---|---|---|
| Focal | Diffuse | 0.5 | Strong | Weak | |||
| No. (%) | No. (%) | No. (%) | No. (%) | ||||
| Mucoepidermoid carcinoma (4) | 4 (33.3) | 0 | 4 (100) | 3 (75) | 1 (25) | 0.5 | |
| Adenocystic carcinoma (4) | 4 (33.3) | 1(25) | 3 (75) | 4 (100) | 0 | ||
| Acinic cell carcinoma (1) | 1 (8.3) | 1(100) | 0 | 1 (100) | 0 | ||
| Polymorphous low-grade adenocarcinoma (2) | 2 (16.7) | 0 | 2 (100) | 1 (50) | 1 (50) | ||
| Epithelial-myoepithelial carcinoma (1) | 1 (8.3) | 0 | 1 (100) | 1 (100) | 0 | ||
| Total (12) | 12 (100) | 2 (16.7) | 10 (83.3) | 10 (83.3) | 2 (16.7) | ||
Fig. 4Immunohistochemical expression of calponin in malignant salivary gland tumors X400. A – Diffuse expression in mucoepidermoid carcinoma X100. B – Diffuse expression in polymorphous low-grade adenocarcinoma. C – Diffuse expression in epithelial-myoepithelial carcinoma. D – Diffuse expression in adenocystic carcinoma. E – Mixed distribution of mucoepidermoid carcinoma. F – Mixed distribution in adenocystic carcinoma. G – Solid distribution in adenocystic carcinoma.
Calponin expression in malignant salivary gland tumors in relation to the distribution.
| Malignant salivary gland tumors (12) | Distributions | P-value | |||
|---|---|---|---|---|---|
| Luminal positivity | Abluminal positivity | Luminal & abluminal positivity | Solid Tumor (no duct) | ||
| No. (%) | No. (%) | No. (%) | No. (%) | ||
| Mucoepidermoid carcinoma (4) | 0 | 0 | 4 (100) | 0 | 0.09 |
| Adenocystic carcinoma (4) | 0 | 0 | 2 (50) | 2 (50) | |
| Acinic cell carcinoma (1) | 0 | 0 | 1 (100) | 0 | |
| Polymorphous low grade adenocarcinoma (2) | 0 | 0 | 0 | 2 (100) | |
| Epithelial–myoepithelial carcinoma (1) | 0 | 0 | 0 | 1 (100) | |
| Total (12) | 0 | 0 | 7(58.3) | 5(41.7) | |
Fig. 5Expression of telomerase in salivary gland tumors X400. A – Negative expression in normal salivary glands. B – Diffuse expression in pleomorphic adenoma X100. C – Focal expression in basal cell adenoma. D – Diffuse expression in mucoepidermoid carcinoma. E – Negative expression in mucoepidermoid carcinoma. F – Regional expression in adenocystic carcinoma (arrow). G – Diffuse expression in polymorphous low-grade carcinoma. H – Diffuse expression in epithelial-myoepithelial carcinoma.
Telomerase expression of all salivary gland tumors in relation to immune scoring.
| Salivary gland tumors (30) | Score 0 | Score 1 | Score 2 | Score 3 | P-value | |
|---|---|---|---|---|---|---|
| Negative | Focal | Regional | Diffuse | |||
| No. (%) | No. (%) | No. (%) | No. (%) | |||
| Benign | Pleomorphic adenoma (15) | 1 (6.7) | 0 | 6 (40) | 8 (53.3) | 0.03 |
| Warthin’s tumor (2) | 2 (100) | 0 | 0 | 0 | ||
| Basal cell adenoma (1) | 0 | 1 (100) | 0 | 0 | ||
| Total (18) | 3 (16.7) | 1 (5.6) | 6 (33.3) | 8 (44.4) | ||
| Malignant | Mucoepidermoid carcinoma (4) | 2 (50) | 0 | 0 | 2 (50) | 0.3 |
| Adenocystic carcinoma (4) | 0 | 1 (25) | 2 (50) | 1 (25) | ||
| Acinic cell carcinoma (1) | 0 | 0 | 1 (100) | 0 | ||
| Polymorphous low-grade adenocarcinoma (2) | 0 | 0 | 0 | 2 (100) | ||
| Epithelial-myoepithelial carcinoma (1) | 0 | 0 | 0 | 1 (100) | ||
| Total (12) | 2 (16.7) | 1 (8.3) | 3 (25) | 6 (50) | ||
P < 0.05 significant difference.